Information:
Error:
ID
34292
Description
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function; ODM derived from: https://clinicaltrials.gov/show/NCT02014259
Link
https://clinicaltrials.gov/show/NCT02014259
Keywords
Versions (1)
- 1/16/19 1/16/19 -
Copyright Holder
see on clinicaltrials.gov
Uploaded on
January 16, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Diabetes NCT02014259
Eligibility Diabetes NCT02014259
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes NCT02014259
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
male or female aged 18-85 years (both inclusive) at the time of signing inform consent
boolean
ID.2
Item
subject with normal renal function or renal impairment (mild, moderate, severe or end-stage renal disease requiring dialysis)
boolean
ID.3
Item
for subject with normal renal function: good general health (as judged by the investigator)
boolean
ID.4
Item
body mass index (bmi) 18.5-40.0 kg/m^2 (both inclusive)
boolean
ID.5
Item
female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods
boolean
ID.6
Item
history of crohn's disease, ulcerative colitis, or other inflammatory bowel disease
boolean
ID.7
Item
uncontrolled hypertension (defined as systolic blood pressure above or equal to 180 mmhg and/or diastolic blood pressure above or equal to 100 mmhg)
boolean
ID.8
Item
any blood draw or donation of blood or plasma in excess of 400 ml within the 3 months preceding the screening visit (visit 2)
boolean
ID.9
Item
history of significant drug abuse, or a positive drug test at the screening visit (visit 2)
boolean